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Abstract: 
Hypertension is a leading risk factor for disease burden globally. An unresolved question is 
whether grade 1 hypertension (140-159/90-99 mmHg) with low (mortality <1% at 10 
years) to moderate (mortality ≥1% and <5% at 10 years) absolute total cardiovascular risk 
(CVR) should be treated with anti-hypertensive agents. 
A virtual international consultation process was undertaken to summarize the opinions of 
select experts.  After holistic analysis of all epidemiological, clinical, psychosocial and 
public health elements, this consultation process reached the following consensus in 
hypertensive adults aged < 80 years: 1) The question of whether drug treatment in grade 1 
should be preceded by a period of some weeks or months during which only lifestyle 
measures are recommended cannot be evidence based, but the consensus opinion is to have 
a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension 
(grade 1 uncomplicated hypertension with low absolute total CVR, and without risk major 
factors and risk modifiers). 2) The initiation of anti-hypertensive drug therapy in grade 1 
hypertension with moderate absolute total CVR should not be delayed. 3) Men ≥ 55 years 
and women ≥ 60 years with uncomplicated grade 1 hypertension should automatically be 
classified within the moderate absolute total CVR category, even in the absence of other 
risk major factors and risk modifiers. 4) Statins should be considered along with blood-
pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 
hypertensive with moderate CVR. 
Key words: Drugs/Risk factors/Epidemiology/Blood pressure/Cardiovascular disease/ 
Guidelines/ Healthy lifestyle/Prevention/ Hypertension/Risk assessment/ Risk 
management/ Clinical trials/ Risk prediction/ Risk score/ Risk stratification / Treatment 
Nonstandard abbreviations: 
CVD Cardiovascular diseases 
CVR
 
Cardiovascular risk
 
SCORE
 
Systematic Coronary Risk Estimation
 
RCT Randomized clinical trials 
BP
 
Blood pressure 
 
DM Diabetes Mellitus, type 2 
CKD
 
Chronic kidney disease 
 
EUROASPIRE
 
European Action on Secondary and Primary Prevention through 
Intervention to Reduce Events
 
HOPE-3 Heart Outcomes Prevention Evaluation 
NICE National Institute for Health and Care Excellence 
LDL Low density lipoprotein cholesterol  
MESA Multi-Ethnic Study of Atherosclerosis 
SPRINT Systolic Blood Pressure Intervention Trial 
I Introduction 
Hypertension is a leading risk factor that contributes to the burden of global cardiovascular 
disease (CVD).
1,2
 A related controversial but unresolved topic in CVD prevention is 
whether grade 1 hypertension (140-159/90-99 mmHg) with low to moderate absolute total 
cardiovascular risk (CVR) should be treated using anti-hypertensive drugs.
3,4,5,6,7,8  
In this 
consensus, total CVR is defined as follows: low as CVD mortality <1% at 10 years and 
moderate as CVD mortality ≥1% and <5% at 10 years according to the SCORE 
(Systematic Coronary Risk Estimation).
9
 
The elusiveness of the answers to the question posed are chiefly due to the lack of 
randomized clinical trials (RCT) that specifically evaluate treatment with anti-hypertensive 
drugs versus subgroups using placebo adjusted to the current definitions of grades of  
hypertension and absolute total CVR.
9,10,11
 In addition, to be considered are i) recent results 
from meta-analyses,
12,13,14
 ii) variability of clinical and psychosocial factors in subjects with 
grade 1 hypertension and low-moderate absolute total CVR, emphasizing the need for 
individualized pharmacological treatment
4
 and iii) the gap between guideline 
recommendations and the actual treatment of hypertension in clinical practice.
15
    
Although basing clinical guidelines exclusively upon RCT evidence might be considered 
ideal, truly direct evidence-based recommendations for every clinical situation are few, and 
that inconsistent (or even conflicting) data must often be interpreted and extrapolated.
16,17
 
Hence, on a practical basis, many trials have not adequately informed practice.
18
 RCT 
limitations may include i) relatively small samples, ii) highly selected investigators, iii) 
highly selected participants, iv) use of multiple therapies prior to randomized treatments, v) 
inability to answer all possible questions generated during the course of medical practice, 
vi) relatively short duration of controlled trials because of practical limitations—in most 
instances between 3 and 6 years, with an average time to an endpoint of only half of this, in 
order to achieve desired statistical results, vii) unwarranted extrapolation of results using 
one medication to the rest in its class, and viii) underrepresentation of the young, the 
elderly, and non-white populations.
9,16,17,18
 Recommendations for life-long intervention are 
based on considerable extrapolation from data obtained over periods much shorter than the 
life expectancy of most patients. Support for the belief that the benefits measured during 
the first few years will continue over a much longer term comes from observational studies 
of a few decades’ duration. As a corollary, there are no criteria for duration of specific 
treatments during different periods in life.
9
 Thus, it is necessary to create a holistic 
analysis of all epidemiological, clinical, psychosocial and public health elements in 
order to make informed and relevant decisions.  
The aim of this report is to present the results of an international consultation process 
carried out with select experts to explore current opinions, in order to pave the way to 
develop clinical future guideline recommendations about the following question.  
II Question guiding the consultation process 
Should grade 1 hypertension with low to moderate absolute total CVR be treated with anti-
hypertensive medication? 
III Methods 
The initial version of this manuscript was elaborated (by AMS) based on the latest 
guidelines and documents published by the major international hypertension societies, as 
well as several papers of interest for this consultation matter.
19,20,21,22,23,24,25,26,27,28,29,30,31,32
 
This version was sent to 55 select experts, some declined to participate. Finally in ensuing 
phases, a thorough virtual discussion took place among 40 international experts from June 
16, 2016 to Febraury 14, 2017. The review was periodically updated according to the 
suggestions of the experts during the different stages of evaluation, until a consensus 
emerged.  
Several experts were authors and reviewers of the latest Guidelines of the European Society 
of Hypertension (AC, JR, MHO and AZ),
19
 the Latin-American Society of Hypertension 
(PLJ, RS, ABM, JPC, FL, AR and AZ),
30
 International/American Society of Hypertension
 
(AR, MW, JW, AS)
21
 and Joint European Task Force of Cardiovascular Prevention
 
(JR)
9
. 
Besides, some expert were authors of recently statements from World Heart Federation (SY 
and DP)
27
, World Hypertension League (MO)
29
, Lancet Commission on Hypertension 
(MOH, PLJ, AES and JW)
24
, Blood Pressure Lowering Treatment Trialists’ Collaboration 
(JS)
31
 and Working Group on the Summit on Combination Therapy for CVD (SY)
32
 among 
others.  
The authors, contemplate that this document could evolve as new information emerges. 
IV What was recommended by the European Guidelines?  
The 2013 European Guidelines recommend that the initiation of pharmacological treatment 
should be considered in grade 1 hypertension patients at low to moderate absolute total 
CVR, when blood pressure (BP) remains in this range during repeated visits, including after 
a reasonable trial of lifestyle modification, or is elevated by ambulatory BP criteria (Class 
IIa, Level B).
19
 The same recommendation is considered as Class IIb, Level B by the 2016 
European Guidelines on CVD Prevention.
9
 
The 2013 European Guidelines suggest beginning the initial control of hypertension with 
lifestyle changes over a few weeks alone in the following categories:
19
 
1. Grade 1 hypertension (140-159/90-99 mmHg) and low absolute total CVR or no 
additional risk factors (lifestyle changes alone could be tried for a period of between 3-6 
months).  
2. Grade 1 hypertension and moderate absolute total CVR (with 1 or 2 additional risk 
factors). 
3. Grade 1 hypertension with moderate-high absolute total CVR (with ≥ 3 risk factors). 
Lowering BP with drugs should not be delayed when the patients have diabetes mellitus 
(DM), evidence of target organ damage, chronic kidney disease (CKD) grade ≥ 3, 
symptomatic CVD or grade 3 hypertension (systolic BP ≥180 mmHg and/or diastolic BP ≥ 
110 mmHg).
19
 
European Guidelines on CVD prevention state that lifestyle measures (weight control, 
increased physical activity, alcohol moderation, sodium restriction in those with high 
consumption, and increased consumption of fruits and vegetables) are recommended in all 
patients with hypertension (Class I, Level A).
9 
 
The relationship between BP and CVD morbidity and mortality is modified by the presence 
of other risk factors.
19,31
 The 2013 European Hypertension Guidelines recommend that 
decisions on treatment strategies depend on the initial level of absolute total CVR (Class I, 
Level B).
19
 It also advises that in asymptomatic subjects with hypertension but without 
evidence for CVD, CKD and DM, total CVR stratification using the SCORE model is 
recommended as a minimal requirement (Class I, Level B).
18
 In comparison, 2016 
European Guidelines on CVD prevention considered systematic total CVR assessment in 
individuals with hypertension as Class I, Level C.
9
 
 
V Elements Favoring Prompt Use of Anti-Hypertensive Medications in Grade 1 
Hypertension with Low-Moderate Absolute Total CVR. 
Our consultation process has identified several elements that favor early antihypertensive 
pharmacological treatment. Those factors can be divided into four categories (Table 1): 
A. Relating to lifestyle and behavior. 
1. Avoid potential missed opportunities in primary prevention of CVD, because it 
is well known that after the diagnosis of hypertension a proportion of patients do not attend 
their next scheduled appointment; thus, their BP remains uncontrolled. 
2. Lifestyle modifications can be equivalent to drug monotherapy, but their major 
drawback is the low level of adherence over time.
19,33
 In clinical practice, the adherence 
to lifestyle changes is lower than the adherence to pharmacological treatment. Based 
on data in secondary prevention, the EUROASPIRE III (European Action on Secondary 
and Primary Prevention through Intervention to Reduce Events) study reported that body 
weight and physical activity targets were achieved in 18% and 34% of patients, 
respectively, during the period from 2006-2013.
19,34 
The degree of physical activity is often 
self-reported, and is higher compared with data using objective assessment methods.
35
 In 
addition, one year after myocardial infarction, approximately 50% of hypertensive patients 
remained adherent to pharmacological treatment.
19
 EUROASPIRE IV identified some 
improvements in the utilization of the pharmacological recommendations (aspirin, statins 
and beta-blockers) but adherence to lifestyle changes was still very low (nearly half of the 
participants who smoked at the time of their initial coronary event were persistent smokers 
and only 40% achieved a physical activity level of the recommended intensity for at least 
20 minutes one or more times a week).
9,36
 
In general, there is a favorable global trend in control of dyslipidemia and 
hypertension, largely attributed to improvements in pharmacological treatment. 
However, during the same time frame, there has been an increase in the prevalence of 
obesity and DM, two risk factors associated with an unhealthy lifestyle.
9,37 
Evidence 
suggests that the increase in obesity and DM are offsetting gains in morbidity and mortality 
due to improvements in other risk factors. 
3. Adherence to lifestyle changes might not be affordable, feasible, or effective 
over prolonged time periods, and does not significantly improve after the diagnosis of 
hypertension.
38,39,40
 
4. Non-pharmacological therapy is generally insuficient to achieve BP targets.41  
B. Relating to Total CVR 
5. CVR models have limitations.42,43,44 Among others, the specificity ranges of the 
risk models is between 84.5 to 99.3%, but the positive predictive value ranges from 9.5 to 
17.1% and the sensitivity ranges from 3.6 % to 53.4%. 
42,43,44
 Moreover, the differences 
between observed and expected risk levels could be significant within some risk 
percentiles,
45
 especially when unvalidated local risk estimation systems are used.
46,47,48
 For 
example, the differences on the expected average risk for a sample of Koreans subjects 
using the Framingham score (7.65%) and the “local” Korea score (1.67%) is substantial.48 
Recalibration of the Framingham score for the Spanish population showed that the levels of 
absolute total CVR should be different in Spain.
47 
The predictive value of the risk models is 
affected by the presence of  factors that are usually not included in the CVR models, such 
as low physical activity, obesity, being of low socioeconomic status and other 
psychological factors, pre-DM, a family history of premature CVD, or increased 
triglycerides, fibrinogen, apolipoprotein B, lipoprotein(a) levels and high-sensitivity C-
reactive protein.
9
  
In addition, it is important to point out that there are no validated tables for most low and 
middle income countries, where over three quarters of deaths from CVD occur. When non-
recalibrated models are applied, there has been low concordance among scores, which 
generates uncertainty about their utility for clinical intervention.
49
 Some of the qualitative 
risk predictive models recommended for management of hypertension are not based on 
cohort studies; therefore, their predictive capacity may be limited. This is the case 
regarding the scores promoted by the World Health Organization/Pan-American Health 
Organization,
50
 European Hypertension Guidelines
19
 and Latin American Hypertension 
Guidelines
30
. The continuous relationship between the main risk factors and CVD favors 
the use of quantitative risk predictive models such as Framingham and SCORE.
51
 
Another unresolved controversy related to CVR models is the target of prediction, an 
occasionally imprecisely-defined but important variable. This is the case, for example, with 
total cardiovascular mortality (SCORE
9
) or morbidity and mortality of coronary heart 
disease (Framingham
10
 or Pooled Cohort Equations
28
). Recently, an attempt has been made 
to calculate the relationship of major cardiovascular events to cardiovascular death from the 
data in control groups of BP-lowering RCTs.
52
 The ratio was shown to decrease with the 
increase in cardiovascular death rate, in such a way that cardiovascular mortality should be 
multiplied by about 4 in individuals with cardiovascular mortality below 5% in 10 years, by 
about 3 when cardiovascular mortality is between 5 and 10% and by about 2 when 
cardiovascular mortality is above 10% to predict the rate of major cardiovascular events.
52
   
These data indicate that mortality rates may be an unprecise indicator of morbidity, 
particularly in younger hypertensive patients with low CVR.
52,53,54,55,56 
5.1 Risk modifiers 
The presence of risk modifiers may move an individual’s estimated absolute total CVR 
upward; absence of these modifiers should lead to lowering an individual’s estimated risk.9 
There is concordance among the statements of the American College of Cardiology, 
American Heart Association
28
 and European Society of Cardiology
9
 concerning the utility 
of the following risk modifiers: a) family history of premature CVD, b) coronary calcium 
score ≥300 Agatston units or ≥75th percentile for age, c) atherosclerotic plaques 
determined by carotid artery scanning, d) ankle–brachial blood pressure index <0.9 and e) 
high-sensitivity C-reactive protein ≥2 mg/L.9,28 However, there is no agreement concerning 
other important risk modifiers such as: psychosocial risk factors
9
, heart rate (>90 beats/min 
is often a practical surrogate for adrenergic neurohumoral activation and increased 
CVR)
9,57,58,59
, ergo-anthropometric risk
60,61,62,63
, relative total CVR (see section 12.2)
64,65
, 
arterial stiffness
9,19,66,67,68
, hypertension subtype
69,70
, ambulatory BP
9,71,72
, obstructive sleep 
apnoea syndrome
9
, among others.  
5.2 Definition of grade 1 “isolated” hypertension 
For proper CVR stratification it may be useful to define grade 1 “isolated” hypertension as 
patients with grade 1 uncomplicated hypertension, low (absolute and relative) total CVR 
and without other risk major factors and risk modifiers. 
6. Delaying pharmacological therapy increases total CVR, and ensuing risk is often 
not entirely reversible by treatment.
19
 
7. BP  levels in mid-life are directly related to later CVR.73  
8. After publication of the European Hypertension Guidelines19, an enlarged meta-
analysis of patients with grade 1 hypertension reported that BP lowering induced a 
significant reduction in the risk of stroke, major CVD events and all-cause mortality
12
. 
Limitations of that meta analysis  include a considerable proportion of individuals 
using background anti-hypertensive treatment at baseline, a high prevalence of participants 
with DM, and a high overall CVD-mortality risk of  6.2% over 10 years (above the upper < 
5% cutoff for moderate total CVR according to the SCORE model).
4,6
   (new paragraph 
here) 
Another recent meta-analysis has identified RCTs in which mean untreated baseline BP 
was within the grade 1 hypertension range, and found that in grade 1 hypertension with low 
to moderate absolute total CVR approximately 21 strokes, 34 major CVD events and 19 
deaths could be prevented for every 1000 patients treated for 5 years (number needed to 
treat for 5 years to prevent one stroke=47, one major CVD event= 34, and one death= 19).
13
 
The results of this meta-analysis provides a higher level of evidence for recommendations 
in grade 1 hypertension with moderate CVR.
13
 In this meta-analysis the CVD mortality rate 
of the control group was 4.5% over 10 years,
13
 that is within the moderate CVR range, but 
above the low-risk range (<1%). Furthermore, the use of “mean” baseline values to define 
grade 1 hypertension cannot exclude that a minority of patients with higher BP were 
included, although the number of these patients is likely to be small because the average 
BPs were near the middle value of the range.
13
  
9. The HOPE-3 (Heart Outcomes Prevention Evaluation) RCT showed that 
participants with at least moderate absolute total CVR (men ≥ 55 and women ≥ 65 years of 
age with ≥1 CVR factors but without evidence for prior CV disease), who were in the 
subgroup for the upper third of systolic BP (>143.5 mm Hg) and received active treatment 
(hydrochlorothiazide 12.5 mg and candesartan 16 mg), had significantly lower rates of 
major cardiovascular outcomes than those in the placebo group.
74
 The combination of these 
anti-hypertensive therapies with rosuvastatin (10 mg per day) was associated with the 
greatest reduction in CVR (40%) compared with dual placebo.
75
 The benefits associated 
with this combination were observed in all low density lipoprotein cholesterol (LDL) 
tertiles – i) LDL ≤ 112.3 mg/dl (mean=89.1), ii) LDL 112.4-141.7 mg/dl (mean=126.8) and 
iii) LDL >141.7 mg/dl (mean=166.7)-.
75
 Therefore, a comprehensive, holistic approach 
should be emphasized to reduce CVR to the maximum possible. The addition of statin 
drugs to blood-pressure lowering therapy provides greater benefit in patients with 
grade 1 hypertensive with moderate CVR.
75,76,77,78,79 
One must stress that both the 
American College of Cardiology/American Heart Association and NICE (National Institute 
for Health and Care Excellence) guidelines now focus on an individual’s risk of vascular 
events rather than on their LDL cholesterol concentrations alone.
11,76
 HOPE-3 also supports 
the use of low dose of combination BP lowering therapy in grade 1 hypertenson with 
moderate absolute CVR.
74
 
10. Two-thirds of total CVD events occur in subjects with low to moderate 
absolute CVR, and this proportion could be higher in women (three-quarters). In contrast, 
1/3 of total CVD events occur in subjects with low absolute CVR, with considerable 
gender differences as well (1/4 and 1/2 in men and women, respectively).
45,46
  
11. Although clinicians often require decision thresholds to trigger interventions, in a 
sense this is artificial, since overall risk is actually a continuum, and there is no 
particular point above which, for example, a drug is automatically indicated, nor 
below which lifestyle advice may not usefully be offered.
9,19,80,81
 
12. Age clearly has the most profound influence on the calculation of the absolute 
total CVR.
9,19
 
12.1 All standard absolute total CVR calculators show that older individuals without risk 
factors are still at moderate-high risk. On the other hand, calculators show people <50 years 
as having low CVR, regardless of underlying CVR factors. However, some younger 
individuals are at very high relative CVR compared with individuals of a similar age and 
may have high lifetime CVR; they are more likely to develop CVD early, and may 
prematurely suffer fatal or non-fatal CVD events.
9,19
 For these reasons, efforts to improve 
CVR stratification in youger hypertensive is an important challenge in preventive medicine.  
12.2 Age as a marker of population and individual CVR 
In this context, an age of 55 years seems to be a practical and meaningful dividing line 
because: 
a) The lifetime risk of hypertension is approximately 90% for men and women 
who were nonhypertensive at 55 or 65 years old and survived to age 80 to 85.
41
 
b) Among such people without existing disease, the most discriminatory screening 
factor is age, since over 90% of deaths from ischemic heart disease or stroke, occur in 
people aged 55 and over.
80
 
c) Men ≥ 55 years (women ≥ 60 years) with uncomplicated grade 1 hypertension 
often have moderate total CVR even in the absence of other CVR factors (Figures 1 
and 2). 
Figure 1. Absolute total CVR (13.5%) at 10 years and vascular age (61 years), grade 1 
hypertensive, male, 55 years old, non-smoker, no DM and lipid levels are close to the 
means in the United States of America population.
82
 (Using the Framingham online 
calculator available at https://www.framinghamheartstudy.org/risk-
functions/cardiovascular-disease/10-year-risk.php#) 
 
 
Figure 2. Absolute total CVR (10.3%) and vascular age (74 years) of grade 1 hypertensive, 
female, 60 years old, non-smoker, no DM and lipid levels are close to the means in the 
United States of America population.
82
 
 12.3 Relative total CVR  
One of the most important elements for stratification of grade 1 hypertensive subjects with 
low absolute total CVR is the relative total CVR (the traditional definition uses a ratio of 
the absolute risk of the individual under consideration and the the average absolute risk of a 
baseline population, either a low-risk group or an average risk group).
64,65
 New variants of 
the relative CVR are a) vascular age or risk age
9,83,84
, b) the age and gender total CVR 
percentile
83 
and c) long-term (eg lifetime) risk approach
28
. There is no consensus about 
relative CVR thresholds of low, moderate, and high risk. 
The relative risk (using the traditional concept) and vascular age of the subjects represented 
in Figures 1 and 2 are 2.5 and 61 years, and 3.2 and 74 years in each case.  
Estimation advantages of using relative total CVR are that it:
9,19,64,65,83
  
a) Is independent of the predictive events (“hard” coronary disease, CVD-mortality, etc.),  
b) Can be used in any population independently of the baseline CVR (avoiding the need of 
recalibration),  
c) Reduces or eliminates influence of age on the total CVR. 
This tool can be used to improve adherence, better communicate risk, and guide 
pharmacological anti-hypertensive treatment decisions. However, the guidelines do not 
recommend the use of any relative-CVR variants for treatment decisions.
9,11,19,28
 
12.3.1 Alternatives to relative total CVR 
Age- and gender-specific relative risk has been assessed from other parameters. Among 
them are percentile tables of coronary calcium content according to age and 
gender.
85,86
 MESA (Multi-Ethnic Study of Atherosclerosis) study reported that the CVR at 
> 90 percentile of calcium score (according to age and gender), is double than the absolute 
calcium > 400 Agatston units (18.9 vs 9.94, respectively).
85
  
13 Individuals with a CVR factor at early ages tend to remain in rank-proportional 
levels of risk.
86,87
 
14 Simulation studies have suggested that total CVR-based blood pressure 
management strategies will be more cost-effective than hypertension control strategies 
based solely upon BP numbers,
9,28,42,89,90
 but direct evidence for the role of total CVR in 
treatment decisions is lacking
9,91
 and the best way to reduce total CVR is the control of 
each risk factor. 
15    Grade 1 hypertension with low absolute total CVR is not a benign 
condition.
19
 Even in children and adolescents this combination is associated with increased 
CVR, which is reversible with treatment.
92
 Grade 1 hypertension is associated with 
impaired arterial distensibility that improves with pharmacological treatment.
93
 
16 If the success of BP lowering is measured not only by the absolute reduction in 
outcome it achieves, but also by the absolute level of treatment failures (residual risk)
14
, it 
is not surprising that the greatest success of BP lowering may be actually achieved in 
low-moderate risk patients. Targeting BP-lowering treatment to only those with the 
greatest CVR seems unwarranted because the reduction in the number of patients needing 
treatment to obtain a given benefit is counterbalanced by the dramatic increase in the 
number of patients in whom BP lowering fails to prevent fatal and nonfatal CVD events.
14
 
17 Gaps in knowledge exist about short- and long-term total CVR assessment and 
outcomes in all racial/ethnic groups, across the age spectrum, and in women and men.
28
 
18 Many physicians, rarely or ever use total CVR models.  Yet, essentially all 
applicable guidelines recommend assessment of global CVR prior to pertinent medical 
decision making. Thus, in addition to gaps in knowledge there is a shortfall in CVR model 
utilization. One intriguing, but as-yet untested, solution is the routine inclusion of CVR in 
medical records.
94,95
 
C. Relating to medical management 
19 RCT demonstrate that most hypertensive patients require 2 or more drugs to 
achieve BP control.
19,41
 
20 A large number of safe anti-hypertensive medications are now available, and 
treatment can be personalized in order to optimize both efficacy and tolerability
19
. 
21 Use of traditional algorithms often fails to achieve the desired hypertension 
control
18
, particularly in those less than 75 years of age.
96,97
  
22 Strategies to utilize anti-hypertensive pharmacological treatments earlier in the 
course of grade 1 hypertension and low-moderate absolute total CVR could have an 
important impact on CVD prevention and counteract physician inertia.
98
 Physician 
inertia is considered to be one of the main causes of the low rate of BP control in modern 
anti-hypertensive practices, mainly in youger adults with grade 1 hypertension.
18,99,100
 Often 
it is difficult to tease apart performance deficits due to insufficient treatment advancement 
and poor patient adherence. 
23 The intensity and quality of anti-hypertensive pharmacological treatment is 
one of the key elements in attaining significant improvements of hypertension control 
as well as successful reductions in CVD mortality.
101,102
  
24 Although SPRINT (Systolic Blood Pressure Intervention Trial)103 does not provide 
direct information on the BP level at which drug treatment should be initiated (90% of 
SPRINT patients were already on antihypertensive treatment at baseline). The 
demonstration of cardiovascular benefits in the subgroup of uncomplicated hypertensive 
patients with moderate total CVR,
103
 may be used as indirect support favouring treatment of 
grade 1 hypertension.  
25 High blood pressure is the leading risk factors for death in the world104; and 
anti-hypertensive pharmacological treatment could be the most effective of 
cardiovascular preventive interventions (in primary and secondary prevention).
105,106 
For 
example, in Canada, an increase in the use of pharmacological treatment from 35% to 80% 
was accompanied by significant improvements in hypertension control (13% to 68%).
102
  
26 The initial evaluation of a patient with hypertension should detect causes of 
secondary hypertension, target organ damage and concomitant clinical conditions.
19
 This 
requirement could pose a burden in communities and/or individuals with limited resources.  
Key routine laboratory investigations such as blood chemistries (haemoglobin, 
haematocrit, fasting plasma glucose, cholesterol, uric acid, creatinine, potassium and 
sodium), urine testing (Class I and Level B) and electrocardiograms (Class I and 
Level B) in asymptomatic grade 1 hypertensive adults are not always available.
19
 
Thus, it is often impossible to know whether individual patients in fact already have 
detectable cardiovascular target organ damage, or whether they have concomitant risk.   
D. Relating to socio-economic and public health policies 
27 A proportion of low-income patients with hypertension do not even have the 
resources to try favorable lifestyle changes.
22
 The consumption of fruit and vegetables is 
inadequate worldwide, particularly in low-income countries or in less-affluent people in 
higher income countries, and may be attributed to both difficulty of access and 
unaffordability.
38
  
28 Many anti-hypertensive agents are out of patent, generic, and are therefore 
affordable with acceptable cost–benefit ratios in high income countries.19 Even generic 
drugs that are low cost in high income countries, may be relatively (compared to income) 
expensive in low-middle income countries unless subsidized or provided free by 
governments.
107
 
29 The availability and affordability of healthy lifestyles could be a more signficant 
obstacle than for pharmacological treatment in hypertensive patients, but 
improvements are needed at all levels.
38,108
 
30 The number needed to treat is a concise, epidemiologically useful presentation of 
the effect of an intervention in the short term , but the economic and social analysis of 
pharmacological treatment in young adults requires a different assessment, such as the 
life-years gained-to-years of potential life lost ratio.
109,110 
In addition, the quantitation of 
compression of morbidity and improvement in quality of life remain inexact, leaving 
estimation of the component of disease-free life extension an art rather than science.
109,110
 
31 A population-based primary prevention strategy seeks to reduce the exposure 
to a highly prevalent risk factor for disease.
111
 The effect of current population strategies 
for BP reduction has done little to decrease population systolic BP mean and hypertension 
prevalence.
111
 European Guidelines on CVD prevention state that scientific evidence of the 
impact of food and nutrition policy instruments on outcome measures such as food intake 
and cardiovascular health is  lacking.
9
 Cost-effectiveness studies of the impact of different 
policy options are also limited.
9 
 
Table 1. Main elements favoring early use of drugs in adults aged < 80 years with 
grade 1 hypertension and low to moderate CVR 
Relating to lifestyle and behavior. 
 Avoid missing opportunities in primary prevention of CVD. 
 Adherence to lifestyle changes is lower than to pharmacological treatment. 
 Lifestyle changes might not be affordable or effective over longer periods of 
time. 
 Non-pharmacological therapy is generally insufficient to reach BP targets. 
Relating to Total CVR 
 Predictions using CVR models have limitations. 
 Delaying pharmacological therapy increases total CVR. 
 Two-thirds of CVD events occur in subjects with low to moderate absolute total 
CVR. 
 Direct evidence for the role of total CVR in treatment decisions is lacking. 
 Individuals with a CVR factor at early ages tend to remain at rank-proportional 
levels of risk. 
 Grade 1 hypertension with low to moderate absolute total CVR is not a benign 
condition. 
 Most physicians rarely or never use total CVR models.  
 Assessment of relative CVR may be a key risk modifier in younger hypertensive 
adults, but there is currently no consensus on relative CVR thresholds. 
Relating to medical management  
 Most hypertensive patients require 2 or more drugs to achieve BP control. 
 Treatment can be personalized, optimizing both efficacy and tolerability. 
 Early treatment may minimize later treatment failures. 
 Traditional algorithms often fail to achieve the desired hypertension control, 
particularly in those under 75 years of age. 
 Strategies to utilize anti-hypertensive pharmacological treatments earlier in the 
course of grade 1 hypertension and low-moderate absolute total CVR could have an 
important impact on CVD prevention and counteract physician inertia. 
 Extrapolating evidence from recent meta-analyses and clinical trials may favor 
an aggressive stance.  
 Anti-hypertensive pharmacological treatment could be the most productive of 
cardiovascular preventive interventions. 
 Substantial barriers exist in the detection of secondary hypertension, target 
organ damage, and concomitant clinical conditions, mainly in communities and/or 
individuals with low resources. 
Relating to socio-economic and public health policies 
 The availability and affordability of healthy lifestyle could be a greater obstacle 
than for pharmacological treatment. 
 The economic and social analyses of pharmacological treatment in young adults 
require calculation of the life-years gained-to-years of potential life lost ratio. 
 
 
VI Final considerations  
A. Individual19 and population interventions112,113 are not opposing, but synergistic 
strategies; hypertension management should always take into account the balance between 
clinical and the public health approaches, an issue particularly relevant for low-middle 
income countries.
24,26,27,114
 The cost perspective is a critical component of this balance, 
because governments and individuals need to prioritize how their limited funds are best 
spent. 
9,24,26,27
  
B. This consultation, properly aligned with current global context of the 
cardiovascular prevention comes at a unique time in hypertension management 
philosophy and approach.
9,24,26,27,115,116,117,118
 Indeed,  several relevant partners led by the 
World Health Organization launched an initiative to improve cardiovascular health named 
HEARTS.
24
 The HEARTS technical package covers six elements: healthy lifestyle (counsel 
on CVR factors and self-care), evidence-based treatment protocols (simple and 
standardized protocols), access to essential medicines and technology (a core set of 
affordable medicines and basic technologies), risk-based management (total cardiovascular 
risk assessment, treatment and referral), team care and task-sharing (patient-centered care 
through a team approach and community participation), and systems for monitoring (patient 
and programme monitoring and evaluation).
24
 This global initiative is promoting a set of 
needed major system changes within the delivery of health care to achieve improvements in 
hypertension control.
24
 Therefore, this consultation, properly aligned with this new context 
of the approach to hypertension management, can pave the way to develop a more 
innovative clinical recommendations in the near future. Our attainable goal is a practical 
and standardized algorithm to raise the quality of medical care of patients with 
hypertension and hence, improve control and outcomes.
24,26,27
  
VII Key conclusions 
This consultation process reached the following consensus in hypertensive adults aged < 80 
years (Table 2).  
1. The question of whether drug treatment in grade 1 should be preceded by a period 
of some weeks or months during which only lifestyle measures are recommended cannot be 
evidence based, but the consensus opinion is to have a period of lifestyle alone reserved 
only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension 
with low absolute total CVR, and without other risk major factors and risk modifiers).  
2.  The initiation of anti-hypertensive drug therapy in grade 1 hypertension with 
moderate absolute total CVR should not be delayed.
13,74
 
3. Men ≥ 55 years and women ≥ 60 years with uncomplicated grade 1 hypertension 
should automatically be classified within the moderate absolute total CVR category, even 
in the absence of other risk major factors and risk modifiers.  
4. Statins should be considered along with blood-pressure lowering therapy, 
irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR. 
75,76,77,78
 
Table 2. Management of recently diagnosed grade 1 hypertension with low to moderate 
absolute total CVR in adults aged < 80 years 
Office BP ≥ 140/90 mmHg (or the equivalent in ambulatory BP monitoring)+ 
Not grade 1 “isolated” hypertension Grade 1 “isolated” hypertension++ 
a) In patients with moderate absolute 
total CVR or in patients aged ≥ 55 in men 
(women ≥ 60 year), prescribe both non-
pharmacological and pharmacological 
treatment. 
b) The decision should be individualized 
in other subgroups. 
Promotion of positive lifestyle changes for 
3-6 months while monitoring BP and total 
CVR. 
+Before starting anti-hypertensive drug treatment, most patients should have out-of-office 
monitoring to confirm hypertension. ++ See sections 5.1 and 5.2.  
  
 
VIII Acknowledgements 
The authors thank Drs. Marrugat J, Elosua R, Bayes de Luna A, Grau M, Karmali KN, 
Niebla O, Sacerio E,  Valdés-González Y, De la Noval-García R, Armas-Rojas N, 
Monteagudo-Lima L, Márquez MF, Rodriguez-Gonzalez B, Morejón-Giraldoni AF, 
Alexánderson E, Smith SC, Oparil S, Pozo O, Patel P and Campbell N for their critical 
comments.  
IX References 
1. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global 
Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-
2015. JAMA. 2017;317(2):165-182.  
2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure 
from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 
19·1 million participants. Lancet. 2017;389(10064):37-55.   
3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the 
prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context 
of expectations from prospective epidemiological studies. BMJ 2009;338:b1665. 
4. Zanchetti A. Do we over treat mild hypertension? Expert Opin. Pharmacother. 
2015; 16(8):1121-1126 
5. Anthony J Viera AJ, Hawes EM. Management of mild hypertension in adults. BMJ 
2016;355:i5719 
6. Zanchetti A, Thomopoulos C, Parati G. Randomized Controlled Trials of Blood 
Pressure Lowering in Hypertension A Critical Reappraisal. Circ Res.2015;116:1058-1073 
7. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J. et al. 
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic 
review and meta-analysis.Lancet.2016;387:957-967  
8. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild 
hypertension. Cochrane Database Syst Rev 2012;8:CD006742.pmid:22895954. 
9. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 
European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth 
Joint Task Force of the European Society of Cardiology and Other Societies on 
Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 
societies and by invited experts). Eur Heart J. 2016; 37: 2315–2381 
10. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, 
Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham 
Heart Study. Circulation 2008;117:743–753. 
11. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et 
al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce 
atherosclerotic cardiovascular risk in adults: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation. 
2014;129(suppl 2):S1–S45. 
12. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Effects 
of Blood Pressure Reduction in Mild Hypertension. A Systematic Review and Meta-
analysis. Ann Intern Med. Ann Intern Med 2015;162:184-91 
13. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on 
outcome incidence in hypertension: 2. effects at different baseline and achieved blood 
pressure levels–overview and meta-analyses of randomized trials. J Hypertens. 
2014;32:2296–2304. doi: 10.1097/HJH.0000000000000379. 
14. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on 
outcome incidence in hypertension: 3. effects in patients at different levels of 
cardiovascular risk–overview and meta-analyses of randomized trials. J Hypertens. 
2014;32:2305–2314. doi: 10.1097/HJH.0000000000000380. 
15. Zechmann S, Senn O, Valeri F, Neuner-Jehle S, Rosemann T, and Djalali S the 
FIRE Study Group. The impact of an individualized risk-adjusted approach on 
hypertension treatment in primary care. J Clin Hypertens.2017;00:1–9. 
doi:10.1111/jch.12958 
16. Mancia G. Strengths and limitations of the JNC 8 hypertension guidelines. Nat. 
Rev. Cardiol. 2014;11;189–190 
17. Morales Salinas A, Coca A, Wyss F. Guidelines for Managing High Blood Pressure 
JAMA. 2014;312(3):293-294  
18. Ford I, Norrie J. Pragmatic Trials. N Engl J Med 2016;375:454-63. 
19. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the 
management of arterial hypertension: the Task Force for the Management of Arterial 
Hypertension of the European Society of Hypertension (ESH) and of the European Society 
of Cardiology Eur Heart J. 2013;34(28):2159-219. 
20. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the 
management of high blood pressure in adults: report from the panel members appointed to 
the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. 
21. Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the 
Management of Hypertension in the Community a Statement by the American Society of 
Hypertension and the International Society of Hypertension. J Hypertens.2013;3:3–15. 
22. Weber A, Poulter NR, Schutte AE, Burrell LM, Horiuchi M, Prabhakaran D, et al. 
Is It Time to Reappraise Blood Pressure Thresholds and Targets? A Statement From the 
International Society of Hypertension—A Global Perspective. Hypertension. 2016;68:266-
268. 
23. López-Jaramillo P, Coca A, Sanchez R, Zanchetti A. Hypertension guidelines: Is It 
Time to Reappraise Blood Pressure Thresholds and Targets?. Position Statement of the 
Latin American Society of Hypertension. On behalf of the Latin American Society of 
Hypertension. Hypertension. 2016;68:257-262 
24. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call 
to action and a life course strategy to address the global burden of raised blood pressure on 
current and future generations: The Lancet Commission on hypertension. Lancet. 2016; 
388(10060):2665-2712. 
25. Morales-Salinas A, Wyss F, Coca A, Ramírez AJ, Valdez O, Valerio LF. 
Divergencias entre guías de 2013 y 2014 de la hipertensión arterial. Posición de la Sociedad 
Centroamericana y del Caribe de Hipertensión y Prevención Cardiovascular. Rev Panam 
Salud Publica. 2015;37:172–8.  
26. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, Hennis A, Asma 
S, Angell S. Standardized Hypertension Treatment and Prevention Network. Improved 
Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The 
Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens 
(Greenwich). 2016. 18(12):1284-1294 
27. Adler A, Prabhakaran D, Bovet P, Kazi D, Mancia G, Mungal-Singh V, Poulter N. 
Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood 
Pressure. A World Heart Federation Roadmap. Global Heart. 2015;10(2):111-122 
28. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, 
et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol. 2014; 63:2935–2959. 
29. Campbell NRC, Lackland DT, Niebylski ML, Orias M, Redburn KA, Nilsson PM, 
et al. 2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, 
International Society of Hypertension, and the International Council of Cardiovascular 
Prevention and Rehabilitation. J Clin Hypertens (Greenwich). 2016; 18: 1085-1082 
30. López-Jaramillo P, Sánchez RA, Díaz M, Cobos L, Bryce A, Parra-Carrillo JZ, et 
al. Latin-american consensus of hypertension in patients with type 2 diabetes and metabolic 
syndrome. J Hypertens. 2013; 31: 223-238. 
31. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of 
individual patient data. The Blood Pressure Lowering Treatment Trialists’ Collaboration. 
Lancet 2014; 384: 591–98 
32. Combination pharmacotherapy to prevent cardiovascular disease: present status and 
challenges. Working Group on the Summit on Combination Therapy for CVD. Eur Heart J. 
2014; 35:353–364 
33. Elmer PJ, Obarzanek E, Vollmer WM, Simons-Morton D, Stevens VJ, Young DR, 
Lin PH, Champagne C, Harsha DW, Svetkey LP, Ard J, Brantley PJ, Proschan MA, 
Erlinger TP, Appel LJ. Effects of comprehensive lifestyle modification on diet, weight, 
physical fitness and blood pressure control: 18-month results of a randomized trial. Ann 
Intern Med 2006;144:485–495. 
34. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. 
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug 
therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 
2009;16:121-37. 
35. Dyrstad SM, Hansen BH, Holme IM, Anderssen SA. Comparison of Self-reported 
versus Accelerometer-Measured Physical Activity. Med Sci Sports Exer.2014;46(1):99-
106. doi:10.1249/MSS.0b013e3182a0595f 
36. Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, et al. 
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor 
and therapeutic management of coronary patients from 24 European countries. Eur J Prev 
Cardiol. 2016;23(6):636-48. 
37. Huffman MD, Capewell S, Ning H, et al. Cardiovascular health behavior and health 
factor changes (1988–2008) and projections to 2020. Circulation. 2012;125:2595–602 
38. Miller V, Yusuf S, Chow CK, Dehghan M, Corsi DJ, Lock K, et al. Availability, 
affordability, and consumption of fruits and vegetables in 18 countries across income 
levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 
Glob Health. 2016. http://dx.doi.org/10.1016/S2214-109X(16)30186-3 
39. Kim Y, Kong KA. Do Hypertensive Individuals Who Are Aware of Their Disease 
Follow Lifestyle Recommendations Better than Those Who Are Not Aware? PLoSONE. 
2015; 10(8): e0136858.-xcz doi:10.1371/journal.pone.0136858 
40. Crouch R, Wilson A, Newbury J. A systematic review of the effectiveness of 
primary health education or intervention programs in improving rural women's knowledge 
of heart disease risk factors and changing lifestylebehaviours. Int J Evid Based Healthc. 
2011;9(3):236-45. doi: 10.1111/j.1744-1609.2011.00226.x. 
41. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood 
Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure; National High Blood Pressure Education Program Coordinating 
Committee. The seventh report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 
2003;289(19):2560-72. 
42. Elosua R, Morales-Salinas A. Determinación del riesgo cardiovascular global. 
Caracterización, modelización y objetivos de la prevención cardiovascular según el 
contexto socio-geográfico. Rev Esp Cardiol Supl. 2011;11(E):2-12. 
43. Masana L. ¿Qué tablas de riesgo cardiovascular debemos utilizar? Rev Esp Cardiol. 
2007;60(7):690-2 
44. Siontis GCM, Tzoulaki I, Siontis KC, Ioannidis JPA. Comparisons of established 
risk prediction models for cardiovascular disease: systematic review. BMJ 2012;344:e3318 
45. Comín E, Solanas P, Cabezas C, Subirana I, Ramos R, et al. Rendimiento de la 
estimación del riesgo cardiovascular en España utilizando distintas funciones. Rev Esp 
Cardiol. 2007;60:693-702. 
46. Marrugat J, Vila J, Baena-Díez JM, Grau M, Sala J, Ramos R, et al. Validez relativa 
de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del estudio 
REGICOR. Rev Esp Cardiol. 2011;64(5):385–394 
47. Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, et al. Validity of an 
adaptation of the Framingham cardiovascular risk function: the VERIFICA study. J 
Epidemiol Community Health. 2007;61:40-7. 
48. Jung Ko M, Jung Jo A, Mi Park C, Jeong Kim H, Jung Kim Y, Park DW, et al. 
Level of Blood Pressure Control and Cardiovascular Events: SPRINT Criteria Versus the 
2014 Hypertension Recommendations. J Am Coll Cardiol. 2016;67(24):2821-2831 
49. Bazo-Alvarez JC, Quispe R, Peralta F, Poterico JA, Valle GA, Burroughs M, Pillay 
T, et al. PERU MIGRANT Study; CRONICAS Cohort Study Group. Agreement Between 
Cardiovascular Disease Risk Scores in Resource-Limited Settings: Evidence from 5 
Peruvian Sites. Crit Pathw Cardiol. 2015;14(2):74-80 
50. World Health Organization. Prevention of cardiovascular disease: guidelines for 
assessment and management of total cardiovascular risk. Geneva: WHO Library;2007: 
Available on:: http://www.who.int/cardiovascular_diseases/guidelines/Full%20text.pdf 
51. Morales Salinas A. Debajo del “Iceberg Clínico” en la evaluación del riesgo 
cardiovascular. Hipertensión (Madr) 2006; 23: 132-3. 
52. Zambon A, Arfè A, Corrao G, Zanchetti A. Relationships of different types of event 
to cardiovascular death in trials of antihypertensive treatment: an aid to the definition of 
total cardiovascular risk in hypertension. J Hypertens 2014;32:495-508. 
53. Jørstad HT, Colkesen EB, Boekholdt SM, Tijssen JG, Wareham NJ, Khaw KT, et 
al. Estimated 10-year cardiovascular mortality seriously underestimates overall 
cardiovascular risk. Heart. 2016;102(1):63-8. 
54. Morales Salinas A, Martinez Espinosa C. Comment on “Comparison of the 
REGICOR and SCORE Function Charts…”Rev Esp Cardiol. 2007;60(11):1211-5 
55. Ramos R, Solanas P, Subirana I, Vila J. Comparación entre la tabla del SCORE y la 
función de Framingham-REGICOR en la estimación del riesgo cardiovascular. Med Clin 
(Barc). 2007;128:477. 
56. Marrugat J, Sala J. Nuevos instrumentos, y los riesgos de siempre. Rev Esp Cardiol. 
2007;60:464-7. 
57. Curtis BM, O’keefe JH. Autonomic Tone as a Cardiovascular Risk Factor: The 
Dangers of Chronic Fight or Flight. Mayo Clin Proc. 2002;77(1):45-54. 
58. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the Autonomic Nervous 
System in Atrial Fibrillation: Pathophysiology and Therapy. Circ Res. 2014 April 25; 
114(9): 1500–1515 
59. Zhang K, Rao F, Rana BK, Gayen JR, Calegari F, King A. Autonomic Function in 
Hypertension : Role of Genetic Variation at the Catecholamine Storage Vesicle Protein at 
the Chromogranin B. Circ Cardiovasc Genet. 2009;2:46-56  
60. Li TY, Rana JS, Manson JE, Willett WC, Stampfer MF, Colditz GA, et al. Obesity 
as compared with physical activity in predicting risk of coronary heart disease in women. 
Circulation. 2006;113(4):499–506. 
61. Weinstein AR, Sesso HD, Lee IM, Rexrode KM, Cook NR, Manson JE, et al. The 
joint effects of physical activity and body mass index on coronary heart disease risk in 
women. Arch Intern Med. 2008;168(8):884–90. 
62. Morales Salinas, Coca A. Obesidad, actividad física y riesgo cardiovascular: 
clasificación ergo-antropométrica, variables farmacológicas, biomarcadores y “paradoja del 
obeso”. Med Clin (Barc).2010;134(11):492–8. 
63. Morales Salinas A. Ergo-Anthropometrics: Joining Fit to Fat to Predict 
Cardiovascular Risk. MEDICC Review. 2011; 13(2):52-52 
64. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of 
Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations A Statement 
for Healthcare Professionals From the American Heart Association and the American 
College of Cardiology. Circulation. 1999;100:1481-1492. 
65. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. 
Prediction of coronary heart disease using risk factor categories. Circulation.1998;97:1837-
47. 
66. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR, 
et al. Recommendations for improving and standardizing vascular research on arterial 
stiffness: a scientific statement from the American Heart Association. 
Hypertension.2015;66:698–722. 
67. Brandão AA, Amodeo C, Alcântara C, Barbosa E, Nobre F, Pinto F, et al . I Luso-
Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017. DOI: 
10.5935/abc.20170011 
68.  Velocidad de la onda de pulso: relevancia de la edad en normotensión, hipertensión 
limítrofe e hipertensión esencial. 
69. Yano Y, Lloyd-Jones DM. Isolated Systolic Hypertension in Young and Middle-
Aged Adults. Curr Hypertens Rep. 2016;18:78 
70. Yano Y, Stamler J, Garside DB, Daviglus ML, Franklin SS, Carnethon MR, et al. 
Isolated systolic hypertension in young and middle-aged adults and 31-year risk for 
cardiovascular mortality: the Chicago Heart Association Detection Project in Industry 
study.J Am Coll Cardiol. 2015;65:327–35. 
71. Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, et 
al. The 2015 Canadian Hypertension Education Program recommendations for blood 
pressure measurement, diagnosis, assessment of risk, prevention, and treatment of 
hypertension. Can J Cardiol. 2015 May;31(5):549- 68.  
72. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al. European 
Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum 
Hypertens 2010;24:779–785. 
73. Allen N, Berry JD, Ning H, Horn LV, Dyer A, Lloyd-Jones DM. Impact of Blood 
Pressure and Blood Pressure Change During Middle Age on the Remaining Lifetime Risk 
for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project. Circulation. 
2012;125(1):37–44. 
74. Lonn EM, Bosch J, Lopez-Jaramillo P, Zhu J, Liu L, Pais P, et al.  Blood-Pressure 
Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Eng J Med 
2016; 374(21):2009-20. 
75. Yusuf S, Lonn EM, Pais P, Bosch J, López-Jaramillo P, et al. Blood-Pressure and 
cholesterol lowering in persons without cardiovascular disease. N Eng J Med 2016; 
374(21):2021-2031.  
76. National Institute for Health and Care Excellence. Lipid modification: 
cardiovascular risk assessment and the modification of blood lipids for the primary and 
secondary prevention of cardiovascular disease. NICE guideline CG181 2014. 
https://www.nice.org.uk/guidance/cg181 (accessed Aug 22, 2016). 
77. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. 
Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016. 
doi.org/10.1016/S0140-6736(16)31357-5 
78. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL 
cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of 
individual data from 27 randomised trials. Lancet. 2012; 380: 581–90. 
79. Cushman WC, Goff DC. More HOPE for Prevention with Statins. N Engl J Med 
2016; 374:2085-2087 
80. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 
2002;324:1570-6. 
81. Marrugat J, Elosua R, Icaza G, Morales-Salinas A, Dégano I. Utilidad práctica de 
las funciones de riesgo cardiovascular. Medwave 2016;16(Suppl 4):e6792 doi: 
10.5867/medwave.2016.6792 
82. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in Lipids and 
Lipoproteins in US Adults, 1988-2010. JAMA. 2012;308(15):1545-1554 
83. Cuende JI. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts. Rev 
Esp Cardiol. 2016;69(3):243–246 
84. Lopez-Gonzalez AA, Aguilo A, Frontera M, Bennasar-Veny M, Campos I, Vicente-
Herrero T, et al. Effectiveness of the heart age tool for improving modifiable cardiovascular 
risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 
2015;22:389–96. 
85. Budoff MJ, Nasir K, McClelland RL, Detrano R, Wong N, Blumenthal RS, et al. 
Coronary Calcium Predicts Events Better With Absolute Calcium Scores Than Age-Sex-
Race/Ethnicity Percentiles MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll 
Cardiol 2009;53:345–52 
86. McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J, et al. 
Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and 
Intensification of Antihypertensive Therapy. Circulation. 2017;135:153–165 
87. Vos LE, Oren A, Uiterwaal C, Gorissen WH, Grobbee DE, Bots ML. Adolescent 
blood pressure and blood pressure tracking into young adulthood are related to subclinical 
atherosclerosis: the Atherosclerosis Risk in Young Adults (ARYA) study. Am J Hypertens. 
2003;16:549-55. 
88. Raitakari OT, Juonala M, Kähönen M, Taittonen L, Laitinen T, Mäki-Torkko N, 
Järvisalo MJ, Uhari M, Jokinen E, Rönnemaa T, Åkerblom HK, Viikari JSA. 
Cardiovascular Risk Factors in Childhood and Carotid Artery Intima-Media Thickness in 
Adulthood. The Cardiovascular Risk in Young Finns Study. JAMA. 2003;290(17):2277-
2283.  
89. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M. Individualized 
guidelines: the potential for increasing quality and reducing costs. Ann Intern Med 
2011;154:627–634. 
90. Sundstrom J, Neal B. Replacing the hypertension control paradigm with a strategy 
of cardiovascular risk reduction. Eur Heart J Qual Care Clin Outcomes 2015;1:17-22  
91. Hobbs FDR, Jukema JW, Da Silva PM, Mccormack T, Catapano AL. Barriers to 
cardiovascular disease risk scoring and primary prevention in Europe. Q J Med 2010; 
103:727–739 
92. Litwin M, Niemirska A, Śladowska-Kozlowska J, Wierzbicka A, Janas R, Wawer 
ZT, et al. Regression of target organ damage in children and adolescents with primary 
hypertension. Pediatr Nephrol 2010; 25:2489–2499  
93. Reneman RS, Meinders JM, Hoeks APG. Non-invasive ultrasound in arterial wall 
dynamics in humans: what have we learned and what remains to be solved. Eur Heart J. 
2005;26:960–966 
94. Sekaran NK, Sussman JB, Xu A, Hayward RA. Providing clinicians with a patient’s 
10-year cardiovascular risk improves their statin prescribing: a true experiment using 
clinical vignettes. BMC Cardiovascular Disorders. 2013;13(1):90. 
95. Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of global 
coronary heart disease risk assessment in practice: a cross-sectional survey of a sample of 
U.S. physicians. BMC Health Services Research. 2012;12:20.   
http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-12-20 
96. Hankey GJ. The global and regional burden of stroke. Lancet Glob Health 2013; 
http://dx.doi.org/10.1016/S2214-109X(13)70095-0 
97. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, et al, on behalf of the 
Global Burden of Diseases, Injuries, and Risk Factors Study (the GBD 2010 Study) and the 
GBD Stroke Experts Group. Global and regional burden of ischaemic and haemorrhagic 
strokes in 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 
Glob Health 2013;http://dx.doi.org/10.1016/S2214-109X(13)70089-5. 
98. Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, 
Hendrickx K, Vermeire E.  The concept and definition of therapeutic inertia in 
hypertension in primary care: a qualitative systematic review. BMC Family Practice 
2014;15:130.  
99. Lavoie KL, Rash JA, Campbell TS. Changing Provider Behavior in the Context of 
Chronic Disease Management: Focus on Clinical Inertia. Annu Rev Pharmacol Toxicol. 
2017;57:263-283. doi: 10.1146/annurev-pharmtox-010716-104952.  
100. Johnson HM, Thorpe CT, Bartels CM, Schumacher JR, Palta M, Pandhi N, et al. 
Antihypertensive Medication Initiation Among Young Adults with Regular Primary Care 
Use. J Gen Intern Med 29(5):723–31 
101. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved Blood Pressure Control 
Associated With a Large-Scale Hypertension Program. JAMA. 2013;310(7):699-705  
102. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell RNC. The impact of the 
Canadian Hypertension Education Programme in its first decade. Eur Heart J. 
2009;30:1434–1439 
103. SPRINT Study Research Group. A randomized trial of intensive versus standard 
blood pressure control. N Engl J Med 2015; 373:2103-2116. doi:10.1056/NEJMoa1511939. 
104. Narayan V, Ali MK, Koplan JP. Global Noncommunicable Diseases—Where 
Worlds Meet. N Engl J Med. 2010. doi: 10.1056/ne jmp1002024. 
105. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease 
mortality in England and Wales, 1981-2000. Circulation 2004;109:1101-7. 
106. Kones R. Is prevention a fantasy, or the future of medicine? A panoramic view of 
recent data, status, and direction in cardiovascular prevention. Ther Adv Cardiovasc Dis. 
2011;5(1):61–81. 
107. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability 
and affordability of cardiovascular disease medicines and their effect on use in high-
income, middle-income, and low-income countries: an analysis of the PURE study data. 
Lancet. 2016;387:61-9 
108. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, 
availability, and affordability in 36 developing and middle-income countries: a secondary 
analysis. Lancet. 2008. DOI:10.1016/S0140-6736(08)61762-6 
109. Marchant I, Boissel J-P, Nony P, Gueyffier F. High Risk versus Proportional 
Benefit: Modelling Equitable Strategies in Cardiovascular Prevention. PLoSONE. 
2015;10(11): e0140793.doi:10.1371/journal.pone.0140793 
110. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, 
Lloyd-Jones D, Pandey DK, Sanchez EJ, Schram AP, Whitsel LP; on behalf of the 
American Heart Association Advocacy Coordinating Committee, Council on 
Cardiovascular Disease in the Young, Council on the Kidney in Cardiovascular Disease, 
Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on 
Arteriosclerosis, Thrombosis and Vascular Biology, Council on Clinical Cardiology, and 
Stroke Council. Value of primordial and primary prevention for cardiovascular disease: a 
policy statement from the American Heart Association. Circulation. 2011;124:967–990. 
111. Platt JM, Keyes KM, Galea S. Efficiency or equity? Simulating the impact of high-
risk and population intervention strategies for the prevention of disease. SSM - Population 
Health.2017;3:1–8 
112. World Health Organization. Guidelines for implementation. WHO Framework 
Convention on Tobacco Control. Articles 5.3, 8–14. Geneva:World Health 
Organization,2011. 
113. Mancia G, Oparil S, Whelton PK, McKee M, Dominiczak A, Luft FC, et al. The 
technical report on sodium intake and cardiovascular disease in low- and middle income 
countries by the joint working group of the World Heart Federation, the European Society 
of Hypertension and the European Public Health Association. Eur Heart J. 2017;0:1–9 
114. Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, et al. 
Prevention: A Scientific Statement From the World Heart and Stroke Forum Principles for 
National and Regional Guidelines on Cardiovascular Disease. Circulation 2004;109;3112-
3121 
115. Smyth A, Teo KK, Rangarajan S, O’Donnell M, Rana P, Leong D, et al. On behalf 
of the PURE Study Investigators. Alcohol consumption and cardiovascular disease, cancer, 
injury, admission to hospital, and mortality: a prospective cohort study. Lancet 2015; 368: 
1945-1954. 
116. World Health Organization. A Global Brief on Hypertension: Silent killer, global 
public health crisis. Available at: 
http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf. 
Accessed September 7, 2015. 
117. UN General Assembly. 2011 High Level Meeting on Prevention and Control of 
Non-Communicable Diseases: Political Declaration of the High-Level Meeting of the 
General Assembly on the Prevention and Control of Non-Communicable Diseases. 
DocumentA/66/L.1. New York, NY: United Nations General Assembly, 2011. Available 
at: http://www.un.org/en/ga/ncdmeeting2011. Accessed June 11, 2016. 
118. Vedanthan R, Bernabe-Ortiz A, Herasme OI, Joshi R, Lopez-Jaramillo P, Thrift 
AG, et al. Innovative Approaches to Hypertension Control in Low- and Middle-Income 
Countries. Cardiol Clin.2017;35:99–115 
 
 
